Optimising islet engraftment is critical for successful clinical islet transplantation.
Clinical islet transplantation is currently being explored as a treatment for persons with type 1 diabetes and hypoglycaemia unawareness. Although 'proof-of-principle' has been established in recent clinical studies, the procedure suffers from low efficacy. At the time of transplantation, the isolated islets are allowed to embolise the liver after injection in the portal vein, a procedure that is unique in the area of transplantation. A novel view on the engraftment of intraportally transplanted islets is presented that could explain the low efficacy of the procedure.
Department of Radiology, Oncology and Clinical Immunology, Division of Clinical Immunology, Rudbeck Laboratory, C11, University Hospital, SE 751 85, Uppsala, Sweden. olle.korsgren@klinimm.uu.se
O
O
Korsgren
T
T
Lundgren
M
M
Felldin
A
A
Foss
B
B
Isaksson
J
J
Permert
N H
NH
Persson
E
E
Rafael
M
M
Rydén
K
K
Salmela
A
A
Tibell
G
G
Tufveson
B
B
Nilsson
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D007515:Islets of Langerhans / Q000276:immunology; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D008954:Models, Biological